The management of pain-inflammatory conditions;La gestione degli stati algico-infiammatori

Trends in Medicine

Volumn 11, Issue 4, 2011, Pages 163-177

  Panerai, Alberto E ^a  

^a NONE

Author keywords

Inflammation; Ketoprofen; NSAID; Pain

Indexed keywords

INFLAMMATORY DISEASE; MEDICAL CARE; PAIN; REVIEW;

EID: 83055170930     PISSN: 15942848     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Merskey H, Bogduk N (Eds). Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms, 2nd ed. Seattle: IASP Press, 1994.
2. Manchikanti L, Singh V, Bakhit CE, et al. Interventional techniques in the management of chronic pain: Part 1.0. Pain Physician 2000; 3:7-42. (Pubitemid 32680875)
3. Ji R, Gereau RW, Malcangio M, et al. MAP kinase and pain. Brain Res Rev 2009; 60: 135-48
4. Moore ND. In search of an ideal analgesic for common acute pain Acute Pain 2009; 11:129-137.
5. McCormack KJ, Brune K. Dissociation between the anti-nociceptive and anti-inflammatory effects of the nonsteroidal anti-inflammatory drugs: a survey of their analgesic efficacy. Drugs 1991; 41:533-547. (Pubitemid 21920740)
6. Barbanoj MJ, Antonijoan RM, Gich I. Clinical pharmacokinetics of dexketoprofen. Clin Pharmacokinet 2001; 40:245-262. (Pubitemid 32458152)
7. Cabré F, Fernández MF, Calvo L, et al. Analgesic, antiinflammatory, and antipyretic effects of S(+)-ketoprofen in vivo. J Clin Pharmacol 1998; 38:3S-10S. (Pubitemid 29047343)
8. Bray MA, Ford-Hutchinson AW, Smith MJ. Leukotriene B4: an inflammatory mediator in vivo. Prostaglandins 1981; 22:213-222.
9. Granström E. The arachidonic acid cascade. The prostaglandins, thromboxanes and leukotrienes. Inflammation. 1984; (8 Suppl):S15-S25. (Pubitemid 14017385)
10. Williams RL, Upton R. The clinical pharmacology of ketoprofen. J Clin Pharmacol 1988; 28 (12 suppl):s13-s22.
11. Ambrus JL, Haneiwich S, Chesky L, et al. Improved in-vitro antigen-specific antibody synthesis in two patients with common variable immunodeficiency taking an oral cyclooxygenase and lipoxygenase inhibitor (ketoprofen). J Allergy Clin Immunol 1991; 88:775-783.
12. Dray A, Perkins M. Bradykinin and inflammatory pain. TrendsNeurosci 1993; 16:99-104. (Pubitemid 23048436)
13. Stensrud P, Sjaastad O. Clinical trial of a new anti-bradykinin, antiinflammatory drug, ketoprofen (19.583 r.p.) in migraine prophylaxis. Headache 1974; 14:96-100.
14. Daffonchio L, Rossoni G, Clavenna G, et al. Protective activity of ketoprofen lysine salt against the pulmonary effects induced by bradykinin in guinea-pigs. Inflamm Res 1996; 45:259-264. (Pubitemid 26159999)
15. Matsumoto M, Inoue M, Ueda H. NSAID zaltoprofen possesses novel anti-nociceptive mechanism through blockage of B2-type bradykinin receptor in nerve endings. Neurosci Lett 2006; 397:249-253.
16. O'Connor AB, Dworkin RH. Treatment of neuropathic pain: an overview of recent guidelines. Am J Med 2009; 122 (10 Suppl):S22-S32.
17. Vadalouca A, Siafaka I, Argyra E, et al. Therapeutic management of chronic neuropathic pain: an examination of pharmacologic treatment. Ann N Y Acad Sci 2006; 1088:164-186. (Pubitemid 47092037)
18. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010; 85 (3 Suppl):S3-S14.
19. Ossipov MH, Jerussi TP, Ren K, et al. Differential effects of spinal (R)-ketoprofen and (S)-ketoprofen against signs of neuropathic pain and tonic nociception: evidence for a novel mechanism of action of (R)-ketoprofen against tactile allodynia. Pain 2000; 87:193-199. (Pubitemid 30621451)
20. Irene Díaz-Reval Ma, Ventura-Martínez R, Déciga-Campos M, et al. Involvement of serotonin mechanisms in the antinociceptive effect of S(+)-ketoprofen. Drug Dev Res 2002; 57:187-192.
21. Pert A. Mechanisms of opiate analgesia and the role of endorphins in pain suppression. Adv Neurol 1982; 33:107-122.
22. Jessell TM. The role of substance P in sensory transmission and pain perception. Adv Biochem Psychopharmacol 1981; 28:189-198.
23. Lagerström MC, Rogoz K, Abrahamsen B, et al. A sensory subpopulation depends on vesicular glutamate transporter 2 for mechanical pain, and together with substance P, inflammatory pain. Proc Natl Acad Sci U S A 2011; 108:5789-5794.
24. Torri G, Cecchettin M, Bellometti S, et al. Analgesic effect and beta-endorphin and substance P levels in plasma after short-term administration of a ketoprofen-lysine salt or acetylsalicylic acid in patients with osteoarthrosis. Curr Ther Res 1995; 56:62-69.
25. Diaz-Reval MI, Ventura-Martínez R, Déciga-Campos M, et al. Evidence for a central mechanism of action of S-(+)-ketoprofen. Eur J Pharmacol 2004; 483:241-248. (Pubitemid 38068406)
26. Biörkmann R. Central antinociceptive effects of nonsteroidal antiinflammatory drugs and paracetamol: experimental studies in the rat. Acta Anaesthesiol Scand Suppl 1995; 103:1-44.
27. Sarzi-Puttini P, Atzeni F, Lanata L, et al. Pain and ketoprofen: what is its role in clinical practice? Reumatismo 2010; 62:172-188.
28. Natale F. Studio in soggetti volontari sani della biodisponibilità relativa e della farmacocinetica di ketoprofen dopo somministrazione per via orale sotto forma di sale di lisina in formulazione bustine di granulato (dose singola e ripetuta) e in forma di ketoprofen acido formulato in capsule. Report Interno Dompè 1991.
29. Panerai A, Pignataro O. Flogosi delle vie aeree: nuove prospettive terapeutiche. Otorinolaringologia 1994; 44: 5 (Suppl 1).
30. Memeo A, Cosentina R. Ketoprofen lysine treatment of painful manifestations of spinal osteoarthrosis. Clin Ter 1988; 126:119-122.
31. Mitchell WS Scott P, Kennedy AC, et al. Clinico-pharmacological studies on ketoprofen ("Orudis"). Curr Med Res Opin 1975; 3:423-430.
32. Chevallard M, Mele G, Borsa M, et al. Effectiveness and tolerability of ketoprofen lysine, once a day, in patients with rheumatic disorders. Drugs Exp Clin Res 1987; 13:293-296. (Pubitemid 17118593)
33. Ong CK, Seymour RA, Lirk P, et al. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg 2010; 110:1170-1179.
34. Sinatra RS, Torres J, Bustos AM. Pain management after major orthopaedic surgery: current strategies and new concepts. J Am Acad Orthop Surg 2002; 10:17-29.
35. Reuben SS, Buvanendran A. Preventing the development of chronic pain after orthopaedic surgery with preventive multimodal analgesic techniques. J Bone JointSurg Am 2007; 89:1343-1358. (Pubitemid 46898008)
36. Shah S, Soomro M, Kella U, et al. Comparative study of non steroidal anti inflammatory drugs in postoperative pain. J Surg Pak Dec 2003; 8:2-5.
37. Langlais F, Bourgin T, Maignan JM, et al. Comparative study of ketoprofen and pethidine in severe postoperative pain. Ann Fr Anesth Reanim 1987; 6:408-412.
38. Turek MD, Baird WM. Doubleblind parallel comparison of ketoprofen (Orudis), acetaminophen plus codeine, and placebo in postoperative pain. J Clin Pharmacol 1988; 28 (12 Suppl):S23-S28.
39. Hikiji H, Takato T, Shimizu T, et al. The roles of prostanoids, leukotrienes, and platelet-activating factor in bone metabolism and disease. Prog Lipid Res 2008; 47:107- 126.
40. Raisz LG. Prostaglandins and bone: physiology and pathophysiology. Osteoarthritis Cartilage 1999; 7:419-421. (Pubitemid 29331567)
41. Blackwell KA, Raisz LG, Pilbeam CC. Prostaglandins in bone: bad cop, good cop? Trends Endocrinol Metab 2010; 21:294-301.
42. Fiorentino S, Melillo G, Fedele G, et al. Ketoprofen lysine salt inhibits disuse-induced osteopenia in a new non-traumatic immobilization model in the rat. Pharmacol Res 1996; 33:277-281. (Pubitemid 26383689)
43. Martins MV, da Silva MA, Medici Filho E, et al. Evaluation of digital optical density of bone repair in rats medicated with ketoprofen. Braz Dent J 2005; 16:207-212. (Pubitemid 43271774)
44. Matsumoto MA, De Oliveira A, Ribeiro Junior PD, et al. Short-term administration of non-selective and selective COX-2 NSAIDs do not interfere with bone repair in rats. J Mol Histol 2008; 39:381-387.
45. Robb G, Arroll B, Reid D, Goodyear- Smith F. Summary of an evidence-based guideline on soft tissue shoulder injuries and related disorders-Part 2: Management. J Prim Health Care 2009; 1:42-9.
46. Fatti F, et al. Valutazione dell'efficacia e tollerabilità di ketoprofen sale di lisina in formulazione in bustine per uso orale in pazienti con affezioni flogistiche dell'apparato muscolo-scheletrico (Reumatismo extra-articolare) studio doppio cieco comparativo a placebo. Data on file, 1991.
47. Robbins D, Taylor MAH, Brown MD, et al. Ketoprofen versus ibuprofen for acute sports injuries: are there differences between nonsteroidal anti-inflammatory drugs? Curr Ther Res 1990; 48:780-789.
48. Davis PJ, Williams HJ. The investigation and management of back pain in children. Arch Dis Child Educ Pract Ed 2008; 93:73-83. (Pubitemid 352039414)
49. Devereaux M. Low back pain. Med Clin North Am 2009; 93:477-501.
50. Chou R, Shekelle P. Will this patient develop persistent disabling low back pain? JAMA 2010; 303:1295-1302.
51. Van der Windt DA, Simons E, Riphagen II, et al. Physical examination for lumbar radiculopathy due to disc herniation in patients with low-back pain. Cochrane Database Syst Rev 2010; 2:CD007431.
52. Chou R. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007; 147:478-491. (Pubitemid 351688341)
53. Negrini S, Giovannoni S, Minozzi S, et al. Diagnostic therapeutic flow-charts for low back pain patients: the Italian clinical guidelines. Eura Medicophys 2006; 42:151-170. (Pubitemid 44048039)
54. Van Tulder M, Becker A, Bekkering T, et al.; COST B13 Working Group on Guidelines for the Management of Acute Low Back Pain in Primary Care. European guidelines for the management of acute nonspecific low back pain in primary care. Eur Spine J 2006; 15 (Suppl 2):S169-S191.
55. Levernieux J, Beaslay N, Seze S. Comparative study between injectable ketoprofen and indometacine in the treatment of lomboradicular pain. Revue Internationale de rhumatologie 1986; 16:171-175.
56. Matsumo S, Kaneda K, Norhara Y. Clinical evaluation of ketoprofen (Orudis) in lumbago-a double blind comparison with diclofenac sodium. Br J Clin Pract 1981; 35:266.
57. Silver FH, Bradica G, Tria A. Relationship among biomechanical, biochemical, and cellular changes associated with osteoarthritis. Crit Rev Biomed Eng 2001; 29:373-391. (Pubitemid 34101645)
58. Lories RJ, Luyten FP. The bone-cartilage unit in osteoarthritis. Nat Rev Rheumatol 2011:43-49.
59. Bondeson J, Wainwright SD, Lauder S, et al. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther 2006; 8:R187.
60. Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011; 7:33-42.
61. Andersson AK, Li C, Brennan FM. Recent developments in the immunobiology of rheumatoid arthritis. Arthritis Res Ther 2008; 10:204.
62. Weyand CM, Fujii H, Shao L. Rejuvenating the immune system in rheumatoid arthritis. Nat Rev Rheumatol 2009; 5:583-588.
63. Sanmartí R, Gómez-Centeno A, Ercilla G, et al. Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. Clin Rheumatol 2007; 26:1111-1118. (Pubitemid 46863954)
64. Hetland ML, Stengaard-Pedersen K, Junker P;CIMESTRA study group. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study. Ann Rheum Dis 2008; 67:815-822. (Pubitemid 351829382)
65. Hoes JN, Jacobs JW, Buttgereit F, et al. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 2010; 6:693-702.
66. Farrell M, Gibson S, McMeeken J, et al. Pain and hyperalgesia in osteoarthritis of the hands. J Rheumatol 2000; 27:441-447. (Pubitemid 30095479)
67. Imamura M, Imamura ST, Kaziyama HH, et al. Impact of nervous system hyperalgesia on pain, disability, and quality of life in patients with knee osteoarthritis: a controlled analysis. Arthritis Rheum 2008; 59:1424-1431.
68. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain 2011; 152 (3 Suppl):S2-S15.
69. Willer JC, De Broucker T, Bussel B, et al. Central analgesic effect of ketoprofen in humans: electrophysiological evidence for a supraspinal mechanism in a double- blind and cross-over study. Pain 1989; 38:1-7. (Pubitemid 19184831)
70. Marcolongo R, Canesi B, Ferri S, et al. Efficacy and tolerability of ketoprofen 200 mg controlled-release cps vs indomethacin 50 mg cps in patients with symptomatic hip osteoarthritis. A multicentre study. Minerva Med 1997; 88:383-391. (Pubitemid 27502153)
71. Carrabba M, Chevallard M, Mele G, et al. Ketoprofen lysine in rheumatoid arthritis: efficacy and tolerability of two therapeutic schedules with evaluation of synovial prostaglandin levels. Curr Ther Res 1987; 42:70-76. (Pubitemid 17109847)
72. De Lorenzi C. Dossier registrativo; 1997.
73. Lapicque F, Jankowski R, Netter P, et al. Drug assay in ground tissues: example of ketoprofen diffusion into tonsillar tissue. J Pharm Sci 1990; 79:791-795. (Pubitemid 20308988)
74. Senel S, Erkek N, Karacan CD. Comparison of acetaminophen and ketoprofen in febrile children: a single dose randomized clinical trial. Indian J Pediatr 2011; Epub ahead of print.
75. Principi N. Linee guida terapeutiche dei FANS in pediatria. Minerva Pediatr 1997; 49:379.
76. Celebi S, Hacimustafaoglu M, Aygun D, et al. Antipiretic effect of ketoprofen. Ind J Pediatrics 2009; 76:287-291.
77. Hernandez-Díaz S, García Rodríguez LA. Association Between Nonsteroidal Anti-inflammatory Drugs and Upper Gastrointestinal Tract Bleeding/Perforation - An Overview of Epidemiologic Studies Published in the 1990s. Arch Intern Med 2000; 160:2093-2099. (Pubitemid 30482713)
78. Henry D, Lim LL, García Rodríguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312:1563-1566. (Pubitemid 26188573)
79. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal antiinflammatory drugs. Lancet 1994; 343:769-772. (Pubitemid 24098698)
80. Laporte JR, Ibanez L, Vidal X, et al. Upper gastrointestinal bleeding associated with the use of NSAIDs. Newer versus older agents. Drug Saf 2004; 27:411-420. (Pubitemid 38608459)
81. Donnelly MT, Richardson P, Hawkey CJ, et al. Dose-dependent effects of ketoprofen on the human gastric mucosa in comparison with ibuprofen. Aliment Pharmacol Ther 2000; 14:543-549. (Pubitemid 30240745)
82. Marmo E, Ottavo R, Giordano L, et al. Experimental assessment of some pharmacodynamic features of ketoprofen lysine. Pain relief activity, antipyretic effects, antiinflammatory activity, anti-platelet aggregation activity and interference with the biosynthesis of prostaglandins Arch Sci Med 1980; 137:387-404.
83. Fanelli G, Compagnone C, Loraprile P, et al. Analisi retrospettiva sul profilo prescrittivo di nimesulide nella popolazione italiana afferente agli ambulatori di medicina generale, 2010. Accessibile at www.perimedweb.it/vol-04- 04-retro.pdf
84. McElnay JC, D'Arcy PF. Displacement of albumin bound warfarin by anti-inflammatory agents in vitro. J Pharm Pharmacol 1980; 32:709-711. (Pubitemid 11193193)
85. Sancilio LF, Taylor MA, Mathur PP, et al. Interaction between warfarin and nonsteroidal anti- inflammatory drugs (NSAIDs) in rats. Life Sci 1985; 36:1041-1050. (Pubitemid 15147635)
86. Mieszczak C, Winther K. Lack of interaction of ketoprofen with warfarin. Eur J Clin Pharmacol 1993; 44:205-206. (Pubitemid 23047761)